Diabetes complications and comorbidities

Katherine Tuttle and Jay Shubrook reconvene to discuss what the landmark findings from recent renal outcomes trials mean for clinical practice (16:51).

Primary care physician Jay Shubrook shares his recommendations for diabetes management in a 72-year-old, multi-morbid patient.

Simon Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.

Our clinical advisors discuss their EASD 2019 highlights, including new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial.

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity.

Nephrologist Katherine Tuttle and Primary Care Physician Jay Shubrook discuss referrals to nephrology for patients with comorbid diabetes and kidney disease (8:38).

What does the proliferation of diabetes self-management and monitoring technologies in pediatric care mean for the future of adult services? Katharine Barnard looks at the situation in England and Wales.

Consultant nephrologist Andrew Frankel tells medwireNews about the rationale and key findings of the CREDENCE trial, and discusses the potential benefits of SGLT2 inhibitors beyond type 2 diabetes (9:45).

General practitioner Kevin Fernando talks to medwireNews about the importance of the CREDENCE trial from a primary care perspective (4:43).

Lead investigator Vlado Perkovic talks about the main findings from the CREDENCE trial – demonstrating that canagliflozin is associated with a reduced risk for kidney failure and cardiovascular events in people with type 2 diabetes and chronic kidney disease – and discusses how these results will impact clinical practice (6:51).

Nephrologist and Endocrinologist Katherine Tuttle joins Primary Care Physician Jay Shubrook to share best practice tips for kidney disease screening in patients with diabetes (8:16).

This article discusses the epidemiology, pathophysiology, and bi-directional relationship of diabetes and depression and provides a practical, patient-centered approach to diagnosis and management.

Diabetologist Amar Puttanna addresses growing concerns about the rise of dementia in diabetes care and highlights where guidelines, research efforts, and management options are needed to tackle this comorbidity.

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss the treatment of sight-threatening retinopathy and maculopathy in people with diabetes (9:11).

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss the disease processes that lead to retinopathy in people with diabetes (9:11).

Ophthalmologist Philip Burgess joins Clinical Diabetologist John Wilding to discuss diabetic retinopathy screening and the key role that it plays in reducing vision loss among people with diabetes (10:00).

Jay Shubrook comments on the findings of the multinational DUNE study of glycemic target achievement in people with type 2 diabetes taking insulin.

Lori Berard and Pratik Choudhary address situations that can lead to emergency department admissions in patients using diabetes devices and discuss management strategies tailored to this patient population (9:36).

Pharmacological management of comorbid cardiovascular risk and type 2 diabetes is undergoing a paradigm shift. General practitioner Kevin Fernando puts recommendations from the ADA/EASD into practice in this patient case study.

The effect of sleep duration on glucose regulation and cardiometabolic risk is becoming an increasingly high-profile issue. medwireNews takes a look at the latest evidence, which shows the gravity of the problem but also offers some solutions.